Who are the long-term survivors of recurrent ovarian carcinoma?: a retrospective analysis of a multicenter study

Int J Clin Oncol. 2022 Oct;27(10):1660-1668. doi: 10.1007/s10147-022-02214-9. Epub 2022 Jul 30.

Abstract

Background: The aim of the present study was to investigate the incidence and hallmarks of long-term survivors of recurrent ovarian carcinoma (LTSROC) in a large-scale retrospective cohort of patients from a multicenter study group.

Methods: We performed a regional multicenter retrospective study between January 1986 and September 2021 using clinical data collected under the central pathological review system. Patients who underwent surgery for primary OC at diagnosis and developed recurrent tumors after the initial treatment were included. We defined LTSROC as patients who survived for 5 years or longer after initial tumor recurrence and examined factors affecting the long-term survival of ROC and outcomes of LTSROC.

Results: We collected information on patients with malignant ovarian tumors and finally 657 of them that developed ROC were included in the study population. Sixty-eight (10.4%) patients were LTSROC while 399 (60.7%) were short-term survivors of recurrent ovarian carcinoma. In a multivariate logistic regression analysis, negative ascites cytology [odds ratio (OR) 1.865; 95% CI 1.026-3.393; p = 0.041] and a recurrence-free interval (RFI) of 1 year or longer (OR 2.896; 95% CI 1.546-5.425; p < 0.001) were identified as independent factors associated with LTSROC. Approximately 80% of LTSROC presented with solitary recurrent tumors. Furthermore, more than 50% of LTSROC underwent tumor debulking surgery for the first recurrent tumor with or without chemotherapy.

Conclusion: RFI of 1 year or longer and negative ascites cytology in the initial surgery were identified as independent predictive factors for LTSROC.

Keywords: Long-term survivor; Post-recurrence survival; Recurrent ovarian cancer.

Publication types

  • Multicenter Study

MeSH terms

  • Ascites*
  • Carcinoma, Ovarian Epithelial
  • Female
  • Humans
  • Neoplasm Recurrence, Local / surgery
  • Ovarian Neoplasms* / pathology
  • Retrospective Studies
  • Survivors